Standard Life Aberdeen plc trimmed its position in Colgate-Palmolive (NYSE:CL) by 4.7% in the 4th quarter, HoldingsChannel reports. The firm owned 480,369 shares of the company’s stock after selling 23,638 shares during the quarter. Standard Life Aberdeen plc’s holdings in Colgate-Palmolive were worth $33,069,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently made changes to their positions in the company. Peddock Capital Advisors LLC acquired a new stake in Colgate-Palmolive during the fourth quarter worth about $34,000. Pacifica Partners Inc. acquired a new stake in Colgate-Palmolive during the fourth quarter worth about $36,000. Evoke Wealth LLC acquired a new stake in Colgate-Palmolive during the third quarter worth about $37,000. West Bancorporation Inc. acquired a new stake in Colgate-Palmolive during the fourth quarter worth about $38,000. Finally, Keebeck Wealth Management LLC acquired a new stake in Colgate-Palmolive during the fourth quarter worth about $39,000. Hedge funds and other institutional investors own 77.84% of the company’s stock.
In other Colgate-Palmolive news, CEO Noel R. Wallace sold 5,857 shares of Colgate-Palmolive stock in a transaction on Monday, February 24th. The stock was sold at an average price of $75.43, for a total value of $441,793.51. Following the sale, the chief executive officer now owns 188,393 shares in the company, valued at $14,210,483.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO John W. Kooyman sold 21,294 shares of Colgate-Palmolive stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $76.33, for a total value of $1,625,371.02. Following the completion of the sale, the chief marketing officer now owns 17,676 shares in the company, valued at approximately $1,349,209.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 261,607 shares of company stock worth $19,590,445. 1.14% of the stock is currently owned by company insiders.
Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, January 31st. The company reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. The business had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.93 billion. Colgate-Palmolive had a return on equity of 1,906.25% and a net margin of 15.08%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.74 earnings per share. As a group, analysts expect that Colgate-Palmolive will post 2.96 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Monday, April 20th will be given a dividend of $0.44 per share. This is an increase from Colgate-Palmolive’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Friday, April 17th. This represents a $1.76 dividend on an annualized basis and a yield of 2.76%. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 60.78%.
Several brokerages have commented on CL. TheStreet raised Colgate-Palmolive from a “c+” rating to a “b” rating in a report on Friday, January 31st. Deutsche Bank raised their price objective on Colgate-Palmolive from $72.00 to $73.00 and gave the company a “hold” rating in a report on Thursday, December 12th. Citigroup raised their price objective on Colgate-Palmolive from $71.00 to $78.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Berenberg Bank reissued a “sell” rating and issued a $58.00 price objective on shares of Colgate-Palmolive in a report on Tuesday, February 4th. Finally, Evercore ISI reissued a “buy” rating and issued a $80.00 price objective on shares of Colgate-Palmolive in a report on Monday, January 27th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. Colgate-Palmolive has an average rating of “Hold” and a consensus target price of $74.73.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.
See Also: Death Cross
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.